Home Page

HAMILTON, Bermuda, Sept. 2, 2015 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at three investor conferences:

• Wednesday, September 9 at 4:55 PM at the Baird 2015 Healthcare Conference in New York at the New York Palace hotel
• Thursday, September 10 at 2:00 PM at the BioCentury NewsMakers Conference in New York at the Millennium Broadway Hotel & Conference Center
• Thursday, September 17 at 9:30 AM at the Credit Suisse SMID Conference in New York at the Waldorf Astoria New York

Axovant's management team will present an overview of the company and its lead product candidate, RVT-101, which is expected to enter a confirmatory phase 3 trial for the treatment of mild-to-moderate Alzheimer's disease in the fourth calendar quarter of 2015. 

A live webcast of the Baird and BioCentury presentations will be available through the Axovant website at http://investors.axovant.com/investors/events-and-presentations.aspx, with archived versions available for at least 30 days following each conference.

About RVT-101

RVT-101 is an orally administered, potent antagonist of the 5-HT6 serotonin receptor. Antagonism of the 5-HT6 receptor is a novel mechanism of action that promotes the release of acetylcholine and other neurotransmitters thought to improve cognition and function in patients suffering from Alzheimer's disease and other forms of dementia.  RVT-101 has been studied in 13 clinical trials and dosed in over 1,250 human subjects with a favorable safety and tolerability profile. 

In a 684-subject multinational, double-blind, placebo-controlled study in patients with mild-to-moderate Alzheimer's disease, subjects receiving RVT-101 in combination with donepezil demonstrated statistically significant improvements in cognition and function as compared to subjects receiving donepezil alone.  Axovant intends to commence a confirmatory phase 3 clinical study testing RVT-101 on a background of donepezil therapy in mild-to-moderate Alzheimer's disease patients in the fourth calendar quarter of 2015.  

RVT-101 is an investigational new drug candidate and is not approved for any indication in any markets. 

About Axovant 
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia, a condition characterized by significant decline in mental capacity and impaired daily function. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia, including Alzheimer's disease. 

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding Axovant's expectations about timing of the planned Phase 3 registration program for RVT-101 and other elements of its clinical development and regulatory strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidate RVT-101; and increased regulatory requirements. These statements are subject to the risk that further analyses of the phase 2b data which may lead to different (including less favorable) interpretations of the data than the analyses conducted to date and/or may identify important implications of the phase 2b data that are not reflected in these statements.  Clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant's views of the phase 2b data.  There can be no assurance that the clinical program for RVT-101 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that RVT-101 will ever receive regulatory approval or be successfully commercialized.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see the "Risk Factors" section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2015, and other filings that Axovant makes with the SEC from time to time. These forward-looking statements speak only as of the date of this release. Axovant disclaims any obligation to update these forward-looking statements, except as may be required by law.

Logo - http://photos.prnewswire.com/prnh/20150629/226455LOGO

SOURCE Axovant Sciences Ltd.